Clene(CLNN)
SALT LAKE CITY, UTBiotechnology
Focus: Clene is a publicly traded nanotherapeutics biotech focused on gold nanocrystal-based treatments for neurological diseases including ALS, multiple sclerosis, and Parkinson's disease. The company operates at mid-cap biotech scale with 201–500 employees and is advancing its lead program CNM-Au8 toward FDA filing.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
0
About Clene
AI assessmentNot HiringNo open roles listed right now. Follow Clene to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Clene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
13 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$342K
Pipeline & Clinical Trials
CNM-Au8
ALSClinical Trials (1)
NCT06408727Intermediate Expanded Access Protocol CNMAu8.EAP04
N/AHelp build intelligence for Clene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.